Implementing End-to-End Automation to Achieve Commercial Viability & Scale Autologous Manufacturing from Single-Digit to Hundreds of Patients Weekly

• Integrating automation across manufacturing and analytical testing to reduce turnaround time and achieve competitive advantage in increasingly crowded therapeutic markets
• Scaling automated autologous production from an initial two to three patients per week to hundreds globally while maintaining reliability and meeting contractual delivery commitments
• Reducing the cost of goods from half a million dollars per patient lot to small fractions through comprehensive automation to ensure long-term commercial sustainability

Speakers:

Steven Feldman

Site Head and Scientific Director

Stanford University